Moderna and Merck Release Phase 3 Melanoma Vaccine Data Early After ESMO Leak
Detailed Phase 3 data for Moderna and Merck’s personalized mRNA cancer vaccine, intismeran autogene, reveal a 42% reduction in melanoma recurrence or death when combined with Keytruda, following an unexpected … Read More